Hormone & longevity medicine
Peptide Therapy
Selected peptide treatments, beginning with sermorelin, gonadorelin and topical GHK-Cu, prescribed only after individual evaluation.
Start with a consultationA closer look
Peptides are short chains of amino acids that act as signals in the body. Vitara plans to offer a small number of specific peptides prepared by licensed U.S. compounding pharmacies: sermorelin (injection or dissolving tablet), gonadorelin (injection), and GHK-Cu (topical serum or scalp solution). Compounded medicines are not FDA-approved, and each peptide has its own evidence and risks.
How it works & what research shows
Why this route may fit your needs
SQ injection delivers sermorelin and gonadorelin under the skin, which is how these peptides have been studied. Dissolving tablets avoid needles, but evidence that they work as well as injection is limited. GHK-Cu is offered only as a topical product; injectable GHK-Cu is not offered.
The route must match the prescribed product. Oral options, injection-site risks and your individual health needs are part of the decision.
Mechanism
Sermorelin mimics growth-hormone-releasing hormone, prompting the pituitary gland to release growth hormone. Gonadorelin mimics gonadotropin-releasing hormone, prompting release of the hormones that signal the testes or ovaries. GHK-Cu is a copper-binding peptide found naturally in the body that is studied for its effects on skin repair.
Clinical benefits & evidence
Sermorelin may raise growth-hormone and IGF-1 levels in some adults. Gonadorelin may help maintain natural hormone signaling. Topical GHK-Cu has shown modest improvements in skin appearance in small studies.
Read the science in depth
Research & unanswered questions
Most studies are small or short. Sermorelin's FDA approval was for children, and its commercial product was discontinued for reasons not related to safety. Long-term evidence in adults is limited for all three peptides.
Supporting sources
- Clinical Interventions in Aging: Sermorelin in adult growth-hormone insufficiency
- BioMed Research International: GHK peptide and skin regeneration
- FDA: Bulk drug substances allowed in 503A compounding
Research sources checked 2026-10-03; content reviewed and approved by Vitara’s clinicians. Published studies are not necessarily ongoing or recruiting.
Is this right for you?
A clinician reviews your goals, health history, medicines and, where relevant, blood tests before recommending any peptide. Peptides are not suitable for everyone, including during pregnancy or with certain hormone-sensitive conditions, and an approved medicine or a different approach may be more appropriate.
Your visit
What to expect
Your clinician will explain the recommended treatment, alternatives, and follow-up before you decide whether to proceed.
Before your visit
Personalized preparation instructions will be provided through the patient platform once appointments are available.
After your visit
Treatment-specific aftercare instructions will be provided by the clinical team through the patient platform.
Risks & important considerations
Risks depend on the specific peptide. Injections can cause redness, swelling or pain at the injection site. Sermorelin may cause flushing, headache or dizziness. Gonadorelin can affect hormone levels. Topical GHK-Cu can irritate the skin. Product quality matters, so Vitara uses only licensed pharmacies and does not offer research-only products.
How we reduce risk
Our approach is outlined below. These measures reduce risk but cannot eliminate it.
- Prescribe only specific peptides currently allowed for compounding and supplied by licensed U.S. pharmacies; never research-only or unlabeled products.
- Review health history, medicines and relevant blood tests before starting, and recheck at follow-up visits.
- Explain that compounded peptides are not FDA-approved, discuss approved alternatives, and stop treatment if side effects or abnormal results occur.
Our injection and infusion safeguards
Sources behind this plan
- FDA: Bulk drug substances allowed in 503A compounding
- FDA: Safety concerns for certain compounding ingredients
Sources inform our approach; they do not certify Vitara’s protocols or endorse this service.
Understanding the evidence
Sermorelin was once FDA-approved for growth-hormone deficiency in children; evidence for use in adults is limited. Gonadorelin is used to stimulate the body's own reproductive hormone signals, but evidence for routine use alongside testosterone therapy is limited. GHK-Cu has small studies on skin appearance. Evidence for one peptide does not apply to another.
Sources & further reading
These references provide background information; they do not endorse Vitara or replace individual evaluation.
Common questions
Can I book this treatment now?
Yes. Every visit starts with a consultation, which you can book online from our patient care page.
Where will I complete my medical forms?
Medical intake, consent forms, and patient records will be handled in a separate patient platform. This website does not collect that information.
Approved by Vitara’s clinicians. Availability depends on current FDA compounding rules and pharmacy supply. This page is general education, not medical advice or a complete risk guide; your clinician will discuss your individual risks and options.